KaloBios Announces First Patient Dosed in Phase 1 Study of Lenzilumab for the Treatment of Chronic Myelomonocytic Leukemia

July 25, 2016

Source: Humanigen, Inc.

Released July 25, 2016

©2019 Humanigen, Inc.  All rights reserved